Provided by Tiger Trade Technology Pte. Ltd.

Entrada Therapeutics, Inc.

6.75
-0.1500-2.17%
Post-market: 6.750.00000.00%16:21 EDT
Volume:354.43K
Turnover:2.39M
Market Cap:262.04M
PE:-1.70
High:6.89
Open:6.85
Low:6.60
Close:6.90
52wk High:16.45
52wk Low:5.08
Shares:38.82M
Float Shares:22.98M
Volume Ratio:1.25
T/O Rate:1.54%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.9676
EPS(LYR):-3.4746
ROE:-54.09%
ROA:-29.20%
PB:1.12
PE(LYR):-1.94

Loading ...

Entrada Therapeutics, Inc. Q2 Income from Operations USD -44.963 Million

THOMSON REUTERS
·
Aug 05

Entrada Therapeutics Reports Second Quarter 2026 Financial Results

THOMSON REUTERS
·
Aug 05

Entrada Therapeutics Director, 10% Owner Kush Parmar Disposes of $807,529 in Common Shares

Reuters
·
Aug 04

Entrada Therapeutics Inc Expected to Post a Loss of $1.05 a Share - Earnings Preview

Reuters
·
Jul 31

Xeris Names CEO John Shannon Board Chair, Effective July 1, 2026

Reuters
·
Jun 30

Entrada Therapeutics Stockholders Approve Directors and Equity Plans

TIPRANKS
·
Jun 11

Entrada Therapeutics shareholders approved amendments to 2021 incentive plan, employee stock purchase plan

Reuters
·
Jun 11

Entrada Therapeutics Is Maintained at Buy by Guggenheim

Dow Jones
·
Jun 08

Analysts Have Conflicting Sentiments on These Healthcare Companies: Entrada Therapeutics Inc (TRDA) and Pfizer (PFE)

TIPRANKS
·
Jun 08

Oppenheimer Remains a Buy on Entrada Therapeutics Inc (TRDA)

TIPRANKS
·
Jun 03

Entrada Therapeutics posts corporate deck outlining Duchenne muscular dystrophy, DM1 clinical pipeline milestones

Reuters
·
Jun 02

Entrada Therapeutics clears 10 mg/kg Cohort 2 start in ELEVATE-45-201 DMD trial for ENTR-601-45

Reuters
·
Jun 02

Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 Mg/Kg in Entrada Therapeutics’ Elevate-45-201 Study

THOMSON REUTERS
·
Jun 02

Entrada Therapeutics - on Track to Report Elevate-45-201 Cohort 1 Data in Mid-2026

THOMSON REUTERS
·
Jun 02

Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 Study

GlobeNewswire
·
Jun 02

Entrada Therapeutics grants 18,600 inducement RSUs to new hires under 2025 equity plan

Reuters
·
Jun 02

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jun 02

Entrada director Bernhardt Zeiher acquires $29,316 Entrada common shares

Reuters
·
May 22

Entrada Therapeutics price target lowered to $10 from $19 at Roth Capital

TIPRANKS
·
May 09

HC Wainwright Downgrades Entrada Therapeutics to Neutral From Buy

MT Newswires Live
·
May 08